Previous Investments1
Company | Marketer / Counterparty | Description | Initial Investment Date |
---|---|---|---|
Vertex | Johnson & Johnson | Telaprevir | October 2009 |
Royalty Trust | Astellas | Lexiscan | December 2009 |
CDC | BioDelivery Sciences Ineternational / Meda AB | Onsolis | December 2009 |
MedPro Safety Products | Greiner Bio-One | Vacuette Safety System | October 2010 |
Fosamprenavir Royalty, L.P. | ViiV Healthcare / GSK | Lexiva | December 2010 |
RS Royalty Sub LLC | Pfizer | Lyrica | January 2011 |
CPEX Pharmaceuticals | Auxilium | Testim | April 2011 |
Paradigm Spine, LLC | None | coflex | June 2011 |
1. The investments listed in the table include all of Athyrium’s previously recommended investments that meet the criteria of our current mandates and investment strategies.